GHP Q3 2018

2 GHP / Q3 2018 Editor’s Note , Welcome to Q3 issue of GHP Magazine, your source for the latest news and features from across the healthcare and pharmaceutical industries. In recent news, Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today the European Patent Office has granted the company a patent for its platform ApoGraft™ technology and ApoTainer™ device titled, “Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof”. The patent addresses Cellect’s devices and methods for specifically selecting desired stem cells from a heterogeneous cell population for use in a range of medical indications. In this month’s edition, we discover more about Petosan AS. The firm was established in May 2002, as a result of the veterinarians’ demand for better suited dental care products for pets. We recently spoke with Ole Barman who provided us with an insight into the products the firm produces. Also in this issue, VSM Healthcare’s unique approach to overlaying sector insights and in-depth knowledge enhances its clients’ marketing communications to deliver exceptional and measurable outcomes. We explore the secrets behind the firm’s phenomenal success and how it works to support clients in the healthcare and pharmacy markets. Elsewhere in this edition, TMJ Massage Therapies ® offers a non-invasive and long-lasting pain relief for those plagued by temporomandibular joint (TMJ) dysfunction. Taking time out of her busy schedule, we spoke with Helen Baker, sole practitioner at TMJ Massage Therapies, who revealed more about how she has become the leading expert in this highly- specialised area. Here at GHP Magazine, we hope that you enjoy reading this insightful issue and look forward to hearing from you soon. Jessie Daykin, Editor Phone: +44 (0) 203 970 0037 Email: [email protected] Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.